Shares of BioNTech (BNTX -5.46%) were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Moderna 's (MRNA -7.66%) vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.
Full Answer
What happened to biontech stock in February?
· BioNTech's shares trade at only a little over six times expected earnings. If you think that sales for Comirnaty will remain robust for years to come, today's sell-off makes the stock even more ...
What should investors watch out for with biontech?
· Shares of BioNTech ( BNTX -5.46% ) were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Moderna 's ( MRNA -7.66% ) vaccine might be...
Does Biotech stock have a 15% upside?
· Shares of BioNTech(NASDAQ: BNTX)were trading down by 17.6% as of 11:50 a.m. EDT on Tuesday. The German biotech didn't announce any news that would explain such a decline. Its COVID-19 vaccine ...
Why did biotechs sell-off?
· What happened. Coronavirus stock BioNTech ( BNTX 4.25%) isn't having a good time of it lately. On Wednesday, the company's shares slid yet again, falling by nearly 6% after another coronavirus ...
Why is BioNTech shares down?
Analysts say the slump may simply reflect year-end profit-taking. Both Moderna's and BioNTech's shares have lost half their value since hitting 2021 highs in August and yet are both still up more than 100% for the year. (BioNTech's U.S. depositary receipts are up are 183%, in fact.)
Is BioNTech stock a buy right now?
BioNTech has had an excellent 2021. 2022 and beyond will most likely not be this good, however. The company is very reliant on its COVID vax business today, but BNTX has some attractive pipeline candidates. For risk-hungry investors, BNTX might have value today.
Why did Pfizer stock drop today?
Pfizer shares dropped sharply after the company's 2022 sales guidance appeared to fall short of expectations. The guidance that Pfizer PFE –0.93% (ticker: PFE) presented, however, doesn't take into account future sales of Pfizer's Covid-19 vaccine and antiviral, but only sales already made.
Is BioNTech stock expected to rise?
Stock Price Forecast The 12 analysts offering 12-month price forecasts for BioNTech SE have a median target of 244.77, with a high estimate of 345.95 and a low estimate of 178.08. The median estimate represents a +79.95% increase from the last price of 136.02.
Should I hold BNTX?
The consensus among Wall Street equities research analysts is that investors should "hold" BioNTech stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
Is BNTX stock a good investment?
Analysts expect adjusted earnings to reach $41.596 per share for the current fiscal year. BioNTech SE - ADR does not currently pay a dividend. The Biotechnology and Medical Research sub-industry has a positive outlook, as experts expect strong drug sales growth primarily due to COVID-19.
Will Pfizer shares go up?
There are currently 15 analysts covering Pfizer, and they have a consensus “strong buy” on the stock. Twelve-month price targets range from a low of $50 per share to a high of $75, with an average of $59.80. Based on Pfizer's current price, these predicted gains range from 2.25% to 25.2%.
Is Pfizer a buy Zacks?
How good is it? See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy25.08%2Buy18.56%3Hold10.15%4Sell5.79%2 more rows
Who owns Pfizer stock?
The Vanguard Group, Inc.Top 10 Owners of Pfizer IncStockholderStakeShares ownedThe Vanguard Group, Inc.8.08%456,389,483SSgA Funds Management, Inc.5.04%284,816,832BlackRock Fund Advisors4.69%264,971,345Capital Research & Management Co....4.19%236,858,4166 more rows
Is Biontech a buy Zacks?
How good is it? See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return2Buy18.56%3Hold10.15%4Sell5.79%5Strong Sell2.83%2 more rows
What is the target price for BNTX?
Stock Price TargetHigh$332.38Low$173.79Average$245.55Current Price$158.007 days ago
What is the stock price for Moderna?
$136.26$ 138.78CloseChgChg %$136.26-1.65-1.20%
Researchers might have found some difference between mRNA vaccine makers
Jason covers stocks for the Fool. He leans on his consulting background and executive experience in the human capital management and healthcare industries to offer analysis of individual companies.
What happened
Shares of BioNTech ( NASDAQ:BNTX) were down nearly 7% today after two studies of more than 50,000 patients in the Mayo Clinic Health System showed rival Moderna 's ( NASDAQ:MRNA) vaccine might be more effective against the troublesome delta variant of the SARS-CoV-2 coronavirus.
So what
With so many Americans already vaccinated, the study won't have as much impact as it might have had if it came out earlier this year. Still, it might sway those who remain unvaccinated to seek out the Moderna jab over BioNTech's. There are still more than 700,000 vaccinations happening per day, enough to move the needle financially.
Now what
It may also impact the demand for boosters. Despite the hesitancy of the Food and Drug Administration and the Centers for Disease Control and Prevention, there is little doubt that additional shots to maintain immunity will be necessary.
What is Biontech?
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19
Who said the next decline will be bigger and better?
Famed investor Jeremy Grantham says the next decline will be 'bigger and better' than anything in US history — here are 3 of his safe haven stock picks
Is tech stock volatile in 2021?
Many growth-dependent stocks have seen significant pullbacks in a recent bout of market volatility. Tech stocks have been volatile across 2021's trading, and concerns about rising Treasury bond yields and valuation levels have caused some investors to move out of riskier plays in the sector. With that in mind, a panel of Motley Fool contributors has weighed in with some of their favorite discounted growth picks.
Did Warren Buffett sell dividend stocks?
Warren Buffett recently sold these top dividend stocks, but he could be dead wrong about them — here's why they're still worth buying
What virus roiled the markets on Black Friday?
The fast-spreading strain of coronavirus roiled markets on Black Friday, raising concerns about how the economy and Wall Street may perform next week.
Is Biontech stock trading lower?
Shares of COVID-19 vaccine makers, including BioNTech SE - ADR (NASDAQ: BNTX), are trading lower amid continued volatility in the space as investors weigh booster shot progress. Pfizer CEO Albert Bourla recently predicted a return to 'normal life' within a year with a likely need for annual shots. Shares of companies in growth sectors are also trading lower amid a rise in the 10-year treasury yield. The 10-year Treasury yield hit an intraday high of 1.517% Monday morning before dipping to around
Is Nio a Chinese stock?
Nio is a Chinese stock, and that's just one of the reasons investors in the EV maker are worried.
What happened
Shares of several top COVID-19 vaccine makers were sinking as of 10:22 a.m. ET on Tuesday. BioNTech (NASDAQ: BNTX) was being hit the hardest, with the stock down 9.8%. Shares of Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) had fallen 7.4% and 8.2%, respectively.
Now what
BioNTech and Pfizer expect to have their omicron-specific vaccine ready by March 2022. Moderna hopes to share data with regulators from its testing of an vaccine targeting omicron around the same time.
The Motley Fool
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.
